DongKookPharmaceutical KRX:086450KOSDAQ
동국제약 · Korean news coverage and regulatory filings, organized.
In Q2 2026, DongKookPharmaceutical reported revenue of ₩259bn, up 10.9% year on year, and operating profit of ₩26.1bn. DongKookPharmaceutical (동국제약) appeared in 15 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 9 articles. The most common catalyst was analyst reports (2). It was most often mentioned alongside HD Hyundai Energy Solutions, CJ Cheiljedang and LOTTE rental.
Filing signals Revenue & profit growth Screener
DongKookPharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩259bn | +10.9% | ₩26.1bn margin 10.1% | ₩17.2bn |
| Q1 2026 | ₩251bn | +12.2% | ₩27.3bn margin 10.9% | ₩26.3bn |
| Q4 2025 derived | ₩243bn | +15.1% | ₩24.3bn margin 10.0% | ₩15.6bn |
| Q3 2025 | ₩227bn | +12.9% | ₩24.8bn margin 10.9% | ₩22.3bn |
| Q2 2025 | ₩233bn | +14.7% | ₩22.1bn margin 9.5% | ₩18.1bn |
| Q1 2025 | ₩224bn | +13.7% | ₩25.3bn margin 11.3% | ₩18.0bn |
| Q4 2024 derived | ₩211bn | +12.3% | ₩17.7bn margin 8.4% | ₩8.3bn |
| Q3 2024 | ₩201bn | +13.9% | ₩22.5bn margin 11.2% | ₩21.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
DongKookPharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest DongKookPharmaceutical news Korean headlines
-
[포토]동국제약, 한중브랜드교류회 참석
1 more on this story · 1 outlets
- [포토]동국제약, 상하이 한중브랜드교류회 참석이코노미스트 · Oct 29 14:15
-
Major동국제약 '유레스코정', 비뇨의학회서 급여 적용 필요성 논의
1 more on this story · 1 outlets
- 동국제약 유레스코정, 비뇨의학회서 급여 필요성 논의메디파나뉴스 · Oct 23 12:06